DSF

Department of Pharmaceutical Sciences

SALUMI LIBERI - minimum use of nitrites and nitrates in charcuterie products

Quality and safety of food items are two related and essential yardsticks, of particular importance in the case of fermented and/or processed food products.

In this context, meat and charcuterie products are today important issues. Recently, the IARC (International Agency for Research on Cancer) defined red meat as “probably carcinogenic” (group 2A) and processed meat (cured meats and charcuterie products) as “carcinogenic” (group 1).

Ultra-Fast Silicon Detectors: Enabling Discoveries

The UFSD project sets out to develop a detector of charged particles, which can measure with extreme precision both the position and flight time, able to combine temporal resolutions of ~30 picoseconds with spatial resolutions of 20-30 micron.

The project develops a new technology, silicon detectors with an internal multiplication effect, optimising the design for precise time measurement. Many practical applications are possible, and the project is attracting partners interested in specific developments for various fields of physics.

SIMNOVA - Centro interdipartimentale di Didattica Innovativa e di Simulazione in Medicina e Professioni Sanitarie

Il Centro Interdipartimentale di Didattica Innovativa e di Simulazione in Medicina e Professioni Sanitarie (SIMNOVA) nasce formalmente nel giugno 2014 presso l’Università del Piemonte Orientale. Il SIMNOVA è istituito allo scopo di svolgere attività di alta formazione, ricerca e servizi in ambito sanitario, con particolare attenzione all’uso della simulazione come strumento per innovare i programmi di formazione, migliorare la qualità della cura, ridurre il rischio clinico ed aumentare la sicurezza per i pazienti.

- Identification and validation of COmmon pathways at the CrOssrOads of neurodegeneration and Neuroprotection

Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia in older people in developed countries: it is currently estimated to strike around 5% of people over the age of 65 and around 20% of those over 85.

The only pharmacological treatments currently available for sufferers of AD work to temporarily relieve some symptoms without impacting on its progression. They are the result of pathogenetic hypotheses (for example, the so-called cholinergic hypothesis) formulated some decades ago.